Serum Chemerin Level: Does It Have a Role in Progression of Diabetic Nephropathy
American Journal of Internal Medicine
Volume 4, Issue 2-1, March 2016, Pages: 13-17
Received: Oct. 24, 2015; Accepted: Oct. 26, 2015; Published: Nov. 30, 2015
Views 3809      Downloads 132
Authors
Iman E. El-Gohary, Departments of Internal Medicine, Faculty of Medicine, University of Alexandria, Alexandria, Egypt
Azza Abedl-Karim, Departments of Internal Medicine, Faculty of Medicine, University of Alexandria, Alexandria, Egypt
Doaa I. Hashad, Clinical Pathology Department, Faculty of Medicine, University of Alexandria, Alexandria, Egypt
Article Tools
Follow on us
Abstract
Background: Diabetic nephropathy has become the leading cause of end-stage renal failure in Europe, the United States and Japan (25-44%). Chemerin is a chemoattractant expressed in white adipose, liver and lung tissues. Chemerin is shown to be associated with inflammation which is involved in the pathogenesis of diabetic nephropathy. The aim of the present work is to estimate serum chemerin level and to correlate its level in the patients with the stage of the diabetic nephropathy disease. Patients and Methods: The present study included 60 subjects who were divided into 4 groups Group I: included 15 diabetic patients with norm albuminuria Group II: included 15 diabetic patients with microalbuminuria Group III: included 15 diabetic patients with macroalbuminuria Group IV: included 15 normal subjects as a control group. All patients and controls were subjected to estimation of body mass index. Blood urea, serum creatinine and estimated GFR, Urinary albumin to urinary creatinine ratio, complete lipid profile (LDL, HDL, TG) and Serum chemerin level by ELIZA. Results: Serum chemerin level was higher in diabetic than non-diabetic persons and was higher in patients with macroalbuminuria than those with normo and microalbuminuria and its level is correlated with markers of impaired renal function. Conclusion: chemerin could have a role in progression of diabetic nephropathy or its level could be elevated due to impaired renal excretion which should be further investigated.
Keywords
Diabetic Nephropathy, Chemerin, Albuminuria
To cite this article
Iman E. El-Gohary, Azza Abedl-Karim, Doaa I. Hashad, Serum Chemerin Level: Does It Have a Role in Progression of Diabetic Nephropathy, American Journal of Internal Medicine. Special Issue: Different Medical Research From Middle East. Vol. 4, No. 2-1, 2016, pp. 13-17. doi: 10.11648/j.ajim.s.2016040201.13
References
[1]
Timothy CE, Peter C. Diabetic nephropathy. Clinical Diabetes 2000; 18:278-85.
[2]
Deferrari G, Ropetto M, Calvi C, Ciabattoni M, Rossi C, Robaudo C. Diabetic nephropathy: from micro- to macroalbuminuria. Nephrol Dial Transplant 1998; 3:11-5.
[3]
Schmitz A, Veath M. Microalbuminuria: A major risk factor in non-insulin dependent diabetes. A 10 year follows up study of 503 patients. Diabetes Med 1988; 5:126-34.
[4]
Parving HH, Hovind P. Macroalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy. Curr Hypertens Res 2002; 4: 387-93.
[5]
Ballard DJ, Humphery LL, Melton LJ III. Epidemiology of persistent proteinuria in type II diabetes mellitus. Population-based study in Rochester, Minnesota. Diabetes 1988; 37: 405-12.
[6]
Ernst MC, Sinal CJ. Chemerin at the cross roads of inflammation and obesity. Trends Endocrinol Metab 2010; 21: 660– 7.
[7]
Sell H, Divoux A, Poitou C, Basdevant A, Bouillot JL, Bedossa P, et al. Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J Clin Endocrinol Metab 2010; 95: 2892– 6.
[8]
Lehrke M, Becker A, Greif M, Stark R, Laubender R, Ziegler F et al. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol 2009; 161: 339–44.
[9]
Sell H, Laurencikiene J, Taube A. Chemerin is a novel adipoctye derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes 2009; 58: 2731– 40.
[10]
Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, et al. “Chemerin is a novel adipokine associated with obesity and metabolic syndrome”. Endocrinol 2007; 148: 4687–94.
[11]
Pfau D, Bachmann A, Lossner U, Kratzsch J, Bluher M, Stumvoll M. Serum levels of the adipokine chemerin in relation to renal function. Diabetes Care 2009; 33: 171–3.
[12]
World Health Organization. Obesity: prevention and managing the global epidemic. WHO Obesity Technical Reports Series2000; 894.
[13]
Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function-measured and estimated glomerular filtration rate. NEJM 2006; 354: 2473-83.
[14]
Simerville JA, Maxted WC, Pahira JJ. "Urinalysis: a comprehensive review". American family physician 2005; 71: 1153–62.
[15]
Takahashi M, Takahashi Y, Takahashi K, Zolotaryov FN, Hong KS, et al. Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Letters 2008; 582: 573-8.
[16]
Burtis CA, Ashwood ER, Tietz textbook of Clinical Chemistry, 2nd ed. Philadelphia: WB Saunders, 1994: 1017-89.
[17]
Yang M, Yang G, Dong J, Liu Y, Zong H, Liu H, Boden G, Li L. Elevated plasma levels of chemerin in newly diagnosed type 2 diabetes mellitus with hypertension. J Investig Med. 2010; 58(7): 883-6.
[18]
Saraheimo M, Forsblom C, Thorn L, Wade´n J, Rosenga°rd- Ba¨rlund M, Heikkila¨ O, et al. Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes. Diabetes Care 2008; 31: 1165–9.
[19]
Murata M, Saito T, Otani T, Sasaki M, Ikoma A, Toyoshima H, et al. An increase in serum retinol-binding protein 4 in the type 2 diabetic subjects with nephropathy. Endocr J 2009; 56: 287–94.
[20]
Pfau D, Bachmann A, Lo¨ ssner U, Kratzsch J, Blu¨ her M, Stumvoll M, et al. Serum levels of the adipokine chemerin in relation to renal function. Diabetes Care 2010; 33: 171–3.
[21]
Bozaoglu K, Segal D, Shields KA, Cummings N, Curran JE, Comuzzie AG, et al. Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J Clin Endocrinol Metab 2009; 94:3085–8.
[22]
Lehrke M, Becker A, Greif M, Stark R, Laubender RP, von Ziegler F, et al. Chemerin is associated with markers of inflammation ancomponents of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol 2009; 161:339–44.
[23]
Stejskal D, Karpisek M, Hanulova Z, Svestak M. Chemerin is an independent marker of the metabolic syndrome in a Caucasian population—a pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008; 152: 217–21.
[24]
Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007; 148: 4687–94.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186